ABOUT US

AngioGenex, Inc. is a public company using a promising, exclusively licensed technology (Id platform) from Memorial Sloan Kettering Cancer Center, New York, New York to achieve the following:

Discover and develop anti-cancer drugs that block tumor-associated blood vessel formation, or angiogenesis. The AngioGenex Inc., pipeline of anti-cancer drug candidates includes:
- Small organic molecules for treatment of cancer (AGX51 and related molecules)
- AGX1053, a targeted oligonucleotide
- Monoclonal antibody (mAb)
Clinical development based on synergy with widely prescribed taxanes like paclitaxel (Taxol) providing a rapid and relatively inexpensive development path for anti-Id agents
Strategy to partner with a major pharmaceutical firm after successful completion of the Phase 2a clinical study:
Reliance on contract research organizations (CRO) for all good laboratory practices (GLP), good clinical practices (GCP), and good manufacturing practices (GMP) related activities for Phase 1a,b/2a work
Use monoclonal antibodies of Id for development of highly sensitive assays for blood and tissue suitable for early detection of tumors and to detect recurrence of disease
A commitment to build shareholder value
- A management team experienced in the discovery and development of new drugs
- Low overhead allowing >90% of funds being applied to product goals
- “In and Out” licensing of technology
- Forming alliances and partnerships, not building “bricks & mortar”
- Maintaining and applying “cutting-edge” scientific knowledge and skills in Id area by continuing to work with Dr. R. Benezra, the originator of this technology